PEGylation of liposome decreases the susceptibility of liposomal drug in cancer photodynamic therapy
PEGylation of liposome decreases the susceptibility of liposomal drug in cancer photodynamic therapy
复制标题
DOI：
10.1248/bpb.27.443
复制
发表时间：
2004-03-01
影响因子：
2
通讯作者：
Oku, N
中科院分区：
文献类型：
--
作者：
Ichikawa, K;Hikita, T;Oku, N
为了避免网状内皮系统(Res)被捕获，用聚乙二醇化修饰了用于肿瘤光动力治疗(PDT)的脂质体包裹苯并卟啉衍生物单酸环A(BPD-MA)(PEG-LipBPD-NIA)。BPD-MA在Meth A肉瘤小鼠体内注射后3h的肿瘤蓄积量明显高于未修饰的脂质体BPD-MA(Cont-LipBPD-MA)。相反，只有Cont-LipBPD-MA在PDT后对肿瘤生长有明显的抑制作用，而PEG-LipBPD-MA没有观察到明显的抑制作用。因此，聚乙二醇化增强了脂质体BPD-MA在肿瘤中的被动靶向性，但降低了该药物在光动力疗法中的敏感性。
For the purpose of the avoidance of reticuloendothelial system (RES)-trapping, liposome entrapped benzoporphyrin derivative monoacid ring A (BPD-MA), which is used for cancer photodynamic therapy (PDT), was modified with polyethylene glycol (PEG-LipBPD-NIA). Tumor accumulation of BPD-MA at 3 h after injection with PEG-LipgPD-MA in Meth A-sarcoma-bearing mice was significantly higher than that after injection with non-modified liposomal BPD-MA (Cont-LipBPD-MA) as expected. On the contrary, significant tumor growth suppression after PDT was observed only for Cont-LipBPD-MA but not for PEG-LipBPD-MA. Thus, PEGylation enhances the passive targeting of liposomal BPD-MA in tumor, but decreases the susceptibility of the drug in PDT.